A US subsidiary of Jubilant Life Sciences Company has formed a drug discovery alliance that involves delivering preclinical candidates in the neuroscience field to Belgium’s Janssen Pharmaceutica.
The subsidiary is Bedminster, New Jersey-based Jubilant Discovery Services, which is tying up with Janssen Pharmaceutica (Johnson & Johnson) for an initial three-year period. The alliance will focus on multiple drug targets in the neuroscience category.
Janssen will transfer certain ongoing efforts on selected but unspecified drug discovery targets to Jubilant, while the latter will contribute research services and deliver preclinical candidates to Janssen for possible further development and commercialisation.
As well as receiving (undisclosed) research funding, Jubilant may be eligible for milestones and royalties should Janssen successfully develop and commercialise the drug candidates covered by the alliance, Jubilant noted.
The collaboration will draw on Jubilant’s global research network, including a new research facility in the US focused on neuroscience, as well as the company’s India-based research centres.
Two years ago, Jubilant Biosys launched a neuroscience collaboration – also centred on preclinical outcomes – with AstraZeneca. The partnership was subsequently extended to cardiovascular and metabolic diseases.
Based in Uttar Pradesh, India, Jubilant Life Sciences (formerly Jubilant Organosys) provides drug discovery and development solutions, as well as custom research and manufacturing services, to clients worldwide.
